1761PRisk of health-related quality of life events and pulmonary toxicities in recurrent ovarian cancer patients treated with poly adenosine diphosphate ribose polymerase (PARP) inhibitors maintenance. (23rd October 2018) - Thein, K Z; Sultan, A; Zaw, M H; Han, M M; Yu, N H; Igid, H P; Jones, C; D'Cunha, N; Awasthi, S; Hardwicke, F